Merck KGaA (MRK) Given a €95.00 Price Target by Bank of America Analysts

Bank of America set a €95.00 ($113.10) price objective on Merck KGaA (FRA:MRK) in a report released on Wednesday. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research analysts have also weighed in on the company. Morgan Stanley set a €98.00 ($116.67) price objective on Merck KGaA and gave the stock a neutral rating in a research report on Friday, December 1st. Warburg Research set a €115.00 ($136.90) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, November 29th. Goldman Sachs Group set a €100.00 ($119.05) target price on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, November 29th. Sanford C. Bernstein set a €115.00 ($136.90) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, November 29th. Finally, J P Morgan Chase & Co restated a neutral rating on shares of Merck KGaA in a research note on Tuesday, November 28th. Twelve analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of €107.81 ($128.34).

Merck KGaA (FRA MRK) traded down €0.54 ($0.64) during trading hours on Wednesday, reaching €87.55 ($104.23). The company’s stock had a trading volume of 294,342 shares. Merck KGaA has a 1 year low of €87.33 ($103.96) and a 1 year high of €115.00 ($136.90).

WARNING: “Merck KGaA (MRK) Given a €95.00 Price Target by Bank of America Analysts” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/07/merck-kgaa-mrk-given-a-95-00-price-target-by-bank-of-america-analysts.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply